Trials / Completed
CompletedNCT01276548
A Trial to Evaluate Efficacy and Safety of the Combination Therapy of Genexol®-PM Plus Carboplatin® Compared to Genexol® Plus Carboplatin® as a Firstline Treatment in Subjects With Ovarian Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 102 (actual)
- Sponsor
- Samyang Biopharmaceuticals Corporation · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to Evaluate Efficacy and Safety of the Combination Therapy of Genexol®-PM Plus Carboplatin® Compared to Genexol® Plus Carboplatin® as a Firstline Treatment in Subjects With Ovarian Cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Genexol®-PM 260mg/m2 plus Carboplatin 5 AUC | |
| DRUG | Genexol® 175mg/m2 plus Carboplatin 5 AUC |
Timeline
- Start date
- 2009-10-01
- Primary completion
- 2012-05-01
- Completion
- 2012-09-01
- First posted
- 2011-01-13
- Last updated
- 2017-05-09
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT01276548. Inclusion in this directory is not an endorsement.